Tyra Biosciences (TYRA) Expected to Announce Quarterly Earnings on Thursday

Tyra Biosciences (NASDAQ:TYRA) is expected to announce its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($0.6499) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:00 PM ET.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.04). On average, analysts expect Tyra Biosciences to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Tyra Biosciences Price Performance

Shares of TYRA stock opened at $26.25 on Tuesday. The firm has a market cap of $1.57 billion, a P/E ratio of -10.94 and a beta of 0.77. Tyra Biosciences has a 1-year low of $9.96 and a 1-year high of $40.65. The firm’s 50-day simple moving average is $29.96 and its 200-day simple moving average is $32.66.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on TYRA shares. Guggenheim began coverage on Tyra Biosciences in a research report on Tuesday, April 14th. They issued a “buy” rating and a $54.00 target price for the company. Jefferies Financial Group reissued a “buy” rating and set a $42.00 price target on shares of Tyra Biosciences in a research report on Wednesday, August 5th. Wolfe Research assumed coverage on Tyra Biosciences in a report on Tuesday, May 19th. They issued a “peer perform” rating for the company. Bank of America increased their price objective on shares of Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Finally, HC Wainwright reiterated a “buy” rating and set a $45.00 price objective on shares of Tyra Biosciences in a research note on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $46.90.

Institutional Trading of Tyra Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC increased its stake in shares of Tyra Biosciences by 28.2% in the first quarter. Millennium Management LLC now owns 404,165 shares of the company’s stock valued at $3,759,000 after purchasing an additional 89,024 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Tyra Biosciences by 21.7% during the first quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company’s stock worth $725,000 after buying an additional 13,896 shares during the period. Woodline Partners LP acquired a new position in shares of Tyra Biosciences during the first quarter worth approximately $931,000. Jane Street Group LLC bought a new position in Tyra Biosciences in the 1st quarter worth approximately $324,000. Finally, Geode Capital Management LLC grew its holdings in Tyra Biosciences by 9.8% in the 2nd quarter. Geode Capital Management LLC now owns 567,126 shares of the company’s stock worth $5,428,000 after buying an additional 50,836 shares in the last quarter. 84.14% of the stock is owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.